Avanir's AVP-786 meets in Phase III for Alzheimer's agitation

Avanir said one of two doses of AVP-786 met the primary endpoint of improving agitation symptoms in the Phase III 15-AVP-786-301 trial to treat agitation in patients with Alzheimer's dementia.